First Graphene Ltd (FGR)
Australian Securities Exchange · Australia · prices in AUD · close of 20 Oct 2026
Key indicators
| Last close | AUD 0.054 |
|---|---|
| 52-week range | 0.049 – 0.110 |
| Return, 1 month / 3 months | −1.8% / −6.9% |
| Return, 1 year / 3 years | −39.3% / −29.9% |
| Trend | Below its 200-day average |
| RSI (14) | 52 |
| Volatility (1 year) | 78.4% |
| Worst drawdown (1 year) | -49.5% |
| Average daily value traded | 0.02M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
First Graphene is an Australian company based in Perth that makes graphene products and graphene-enhanced materials. It produces graphene powders and dispersions, along with formulations that incorporate graphene into materials such as composites, coatings, plastics and cement. Its customers are manufacturers and industrial users who add graphene to their products to improve properties such as strength, conductivity and durability. The company also works on developing new graphene applications with research partners and industry.
First Graphene Ltd trades under the code FGR on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
First Graphene Ltd (FGR) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.054 on 20 October 2026.
Its price-based Market X-Ray is 44 out of 100 (a weak price profile), ranking 1,058 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 39.3% and over the last three months it fell 6.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 42 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -15.9% | ||
| From 52-week high | -45.5% | ||
| Momentum | 41 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -6.9% | ||
| 6-month return | -19.4% | ||
| 12-month return, skipping the last month | -38.2% | ||
| Stability (higher is calmer) | 52 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 78.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -49.5% | ||
| Liquidity | 40 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +6.9% |
|---|---|
| 1 month | −1.8% |
| 3 months | −6.9% |
| 6 months | −19.4% |
| 1 year | −39.3% |
| 3 years | −29.9% |
| 5 years | −73.7% |
Signals
| 50-day / 200-day average | 0.055 / 0.064 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.002 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.